We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
Inovio Pharmaceuticals
INO
$69M
| $2M | ﹤0.01% |
96,678
+379
| +0.4% | +$9.7K |
|
|
PTVE
2377
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
| $2M | ﹤0.01% |
228,698
+56,678
| +33% | +$588K |
|
|
NOTV
2378
DELISTED
Inotiv
NOTV
| $1.99M | ﹤0.01% |
118,244
-3,048
| -3% | -$56K |
|
|
RDFN
2379
DELISTED
Redfin
RDFN
| $1.99M | ﹤0.01% |
341,357
-4,735
| -1% | -$42K |
|
|
TRST
2380
Trustco Bank Corp NY
TRST
$938M
| $1.99M | ﹤0.01% |
63,411
-3,140
| -5% | -$104K |
|
2381
Atea Pharmaceuticals
AVIR
$420M
| $1.98M | ﹤0.01% |
347,923
+77,760
| +29% | +$595K |
|
2382
Middlesex Water
MSEX
$1.1B
| $1.98M | ﹤0.01% |
52,475
-1,053
| -2% | -$94.3K |
|
2383
Atara Biotherapeutics
ATRA
$76.1M
| $1.98M | ﹤0.01% |
20,900
+43
| +0.2% | +$4.83K |
|
2384
iShares MSCI Japan ETF
EWJ
$23B
| $1.97M | ﹤0.01% |
+40,328
| New | +$2.16M |
|
2385
BJ's Restaurants
BJRI
$1.48B
| $1.96M | ﹤0.01% |
82,014
-982
| -1% | -$24.2K |
|
|
ACLX
2386
DELISTED
Arcellx
ACLX
| $1.95M | ﹤0.01% |
104,118
+91,236
| +708% | +$1.75M |
|
2387
First Mid Bancshares
FMBH
$1.36B
| $1.95M | ﹤0.01% |
60,929
-972
| -2% | -$35.2K |
|
|
GLDD
2388
DELISTED
Great Lakes Dredge & Dock
GLDD
| $1.94M | ﹤0.01% |
256,325
-5,777
| -2% | -$60.5K |
|
2389
Thryv Holdings
THRY
$108M
| $1.94M | ﹤0.01% |
84,814
-2,042
| -2% | -$50.9K |
|
2390
Bionano Genomics
BNGO
$13.3M
| $1.92M | ﹤0.01% |
1,745
-8
| -0.5% | -$10.6K |
|
2391
Workhorse Group
WKHS
$36.3M
| $1.92M | ﹤0.01% |
223
-3
| -1% | -$29.2K |
|
2392
Goosehead Insurance
GSHD
$2.32B
| $1.91M | ﹤0.01% |
53,701
-1,042
| -2% | -$54.1K |
|
2393
Midland States Bancorp
MSBI
$695M
| $1.91M | ﹤0.01% |
81,112
-26,549
| -25% | -$685K |
|
2394
Vera Therapeutics
VERA
$2.36B
| $1.91M | ﹤0.01% |
89,666
+15,344
| +21% | +$287K |
|
2395
Mission Produce
AVO
$1.17B
| $1.91M | ﹤0.01% |
131,980
-4,154
| -3% | -$63.3K |
|
|
ITOS
2396
DELISTED
iTeos Therapeutics
ITOS
| $1.91M | ﹤0.01% |
100,104
-129,173
| -56% | -$2.98M |
|
|
GBIO
2397
DELISTED
Generation Bio
GBIO
| $1.91M | ﹤0.01% |
35,865
+4,577
| +15% | +$286K |
|
2398
Gorman-Rupp
GRC
$2.21B
| $1.89M | ﹤0.01% |
79,601
-2,109
| -3% | -$57.2K |
|
2399
WisdomTree
WT
$3.22B
| $1.87M | ﹤0.01% |
400,395
-13,217
| -3% | -$67.6K |
|
2400
Anterix
ATEX
$1.94B
| $1.86M | ﹤0.01% |
52,230
+9,839
| +23% | +$408K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.